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Introduction: High-grade gliomas carry a very poor prognosis (1) . Patients when initially diagnosed are treated typically by the combination of surgery, chemo and radiation therapy. Inevitably, tumors will recur.
The disease status in patients with high-grade gliomas is routinely evaluated clinically and radiographically by contrast-enhanced MRI. However, due to the highly heterogeneous nature of these tumors and the complexity of changes induced by the treatment, the structural information derived from these images does not always adequately reflect both the extent of the actual lesion as well as its malignant potential (2, 3) . Biomarkers that are surrogates of proliferative and malignant properties of the tumor and thus can predict treatment responses early and reliably, are under active investigation (4, 5) , Amino acid analogues (6) (7) (8) (9) (10) (11) (12) (13) (14) have been studied for brain tumor imaging. (17) (18) (19) (20) (21) (22) (23) (24) . 18 F-FDOPA uptake in brain tumors is increased compared to normal brain tissue due to the up-regulation of amino acid transport across the blood brain barrier (BBB) by the neutral amino acid transporter. It has been shown previously that 18 F-FDOPA provides excellent visualization of highgrade as well as low-grade brain tumors (17) (18) (19) (20) . Furthermore, its uptake in tumor tissue correlates with tumor grade as well as Ki-67 proliferation index in newly diagnosed gliomas, allowing for a quantitative assessment of malignancy (23) .
This study examines the tumor staging potential and predictive power of power of 18 F-FDOPA for progression-free (PFS) and overall survival (OS) in patients with recurrent high-grade gliomas was assessed. Last, the predictive power of 18 F-FDOPA was compared with MRI and other survival predictors.
PATIENTS AND METHODS:

Patients
Thirty patients with recurrent high-grade gliomas were enrolled prospectively in this study (Table 1 ).
There were 18 males and 12 females with median age of 57.5 (range: 26-78) years. All patients met the following inclusion criteria: they had a histologically confirmed diagnosis of glioblastoma (GBM) or anaplastic astrocytoma (AA) (GBM: N = 24; AA: N = 6) and had previously undergone surgical resection and chemoradiation therapy. All patients had MRI-confirmed recurrent disease by the time bevacizumab treatment was started. Further criteria included a Karnofsky Performance Score (KPS) ≥70, adequate hematological values, and sufficient hepatic and renal function. Patients were excluded if there was a bleeding disorder, a recent history of intracranial bleeding or thromboembolism.
All patients gave written consent to participate in this study, which had been approved by the University of California, Los Angeles, Office for Protection of Research Subjects.
Treatment
All Patients were treated with bevacizumab and irinotecan except for 3 patients who were treated with bevacizumab alone (patient no. 23, 26, and 28, Table 2 ). Co-administration of corticosteroids was closely monitored. While 12 patients did not require corticosteroids, 9 patients were maintained on stable or tapering doses of dexamethasone, and 9 patients needed a dose increase after the baseline MRI and PET studies were obtained.
Research. Patient's disease status was evaluated and monitored using gadolinium enhanced as well as nonenhanced MRI obtained within one week before and at approximately six-week intervals after starting bevacizumab therapy. Patients were followed until death with no subjects lost to follow up. The overall survival (OS) was defined as the interval between treatment initiation and death while progression-free survival (PFS) was defined as the interval between treatment initiation and radiographic and/or clinical progression.
PET Imaging
PET imaging was performed on a dedicated PET system (ECAT HR or HR + ) (25, 26) . Patients were asked to fast for at least 4 hours before image acquisition. 18 F-FDOPA was synthesized according to a previously reported procedure (27, 28) and was injected intravenously at a mean dose of 1.89±0.37 MBq/kg.
Data were acquired in the 3-dimensional mode. The emission scan was started 10 minutes after tracer injection.
To correct for photon attenuation, 5-min transmission scans were acquired after the emission scans for all patients. Images were acquired for 30 minutes in the 3-dimensional mode. Image data acquired between 10 and 30 minutes were summed to obtain a 20 minute static image. PET images were reconstructed using iterative techniques with ordered-subset expectation maximization consisting of 6 iterations with 8 subsets (29, 30) . A Gaussian filter with a full width at half maximum of 4 mm was applied.
Image Analysis
Images were first inspected visually with the axial PET image slice displaying the maximum tumor Tumor ROIs were defined on summed images in two ways. First, a standardized 10 mm circular region was placed over the area with the maximum activity. This was used to derive SUV max and SUV peak . Then, metabolic tumor volume (MTV) was obtained by including all voxels that fall within an SUV threshold determined by the mean SUV of the contralateral striatum (19) . In cases where the tumor involved the striatum bilaterally, a threshold of 1.5 mean SUV of normal hemispheric background was used (19 
Magnetic Resonance Imaging
Data were collected on a 1.5T MRI system (General Electric Medical Systems, Waukesha, WI) using pulse sequences supplied by the scanner manufacturer. Standard anatomical MRI sequences included axial proton density, T1, and T2 weighted fast spin-echo images, along with fluid-attenuated inversion recovery (FLAIR) images, all obtained with a 5mm slice thickness with 1mm inter-slice distance, two excitations, matrix size of 256x256, and a field-of-view of 24cm. Additionally, gadopentetate dimeglumine enhanced (Magnevist; Berlex, Wayne, NJ) axial and coronal T1 weighted images were acquired after contrast injection.
Regions of FLAIR abnormality were chosen based on Response Assessment in Neuro-Oncology (RANO) recommendations (31) . The regions of post-contrast T1-weighted image (T1+C) hyperintensity were defined on post-contrast T1-weighted images, excluding any T1 shortening from blood products on pre-contrast T1-weighted images as well as cystic and surgical resection cavities. The volumes of FLAIR and T1+C were calculated using a semi-automated procedure as described previously (32) .
MRI based response at 6 weeks was defined according to the RANO criteria. However, the 4 week sustained response requirement for complete and partial response was not considered since the goal of the study was to compare the predictive values of MRI and PET at 6 weeks after starting treatment (31) . Progressive disease (PD) was defined as more than a 25% increase in the sum of the products of perpendicular diameters, a significant increase in non-enhancing tumor, or neurologic decline. Complete response (CR) was defined as neither enhancing-nor non-enhancing-tumor, without steroid use. Partial response (PR) was defined as more than a 50% decrease in the sum of the products of perpendicular diameters on stable steroids, without new lesions. Non-enhancing tumor was identified by mass effect and/or architectural distortion including blurring of the gray-white boundary. All scans that did not qualify above were considered stable disease (SD). MRI assessment was performed by a board certified neuroradiologist (W.B.P.).
In addition to assessment using the standard MRI response criteria, tumor volumes by MRI at baseline and follow up scans were also evaluated for response predication.
Statistical Analysis
18
F-FDOPA PET uptake threshold values for treatment response were established by receiver-operatingcharacteristic (ROC) curve analysis. Threshold values derived from this method were scrutinized by leave-oneout cross-validation analysis to assess how robust and sensitive these cutpoints were to individual values. The differences between groups of patients were established by the Student t test. Kaplan-Meier (KM) curves were subsequently generated to obtain survival estimates (33) .
Univariate and multivariate Cox proportional-hazards models were constructed to test the relationship between 18 F-FDOPA metabolic response and other predictors with regard to survival (OS and PFS). The forward stepwise selection technique was utilized to reduce the multivariate models (P < 0.10). Harrell's cindex was used to compare the strength of predictive performance for each model. Furthermore, a permutation simulation study was performed to evaluate the effect of cut-point selection bias on the strength of the association between FDOPA and survival. Survival outcomes were randomly permuted and we recomputed the optimal cut-point for F-FDOPA for prediction of survival. For each of these cut-points we computed the cstatistic. This was done 10,000 times to form an empirical distribution for the optimal c-statistic. The p-value for the observed c-statistic was computed based on the proportion of the simulated c-statistics that were larger than the observed c-statistic. Statistical analyses were performed in SAS (version 9.2; SAS Institute. Cary, NC) and R (version 2.14.2 www.rproject.org).
RESULTS
F-FDOPA-PET Uptake Changes
Research. (Figure 1 ; SUV max 2 weeks: -4.3% ± 15%; 6 weeks: -2.7% ± 19%; 2 -6 weeks: +3.5% ± 22%).
Metabolic tumor volumes, as delineated by 18 F-FDOPA uptake, were determined and are listed in Table   2 . Patients' median MTVs were 24.4 (range 1.6 to 272.3 ml) at baseline, 11.3 (range 1.0 to 181.0 ml) at 2 weeks, and 7.6 (range 0.83 to 115.5) at 6 weeks ( Table 2 ). Significant changes of of -58% ± 16% for responders and -15% ± 17% for non-responders, respectively (P < 0.001). The mean OS was 13.7 months for responders versus 7.0 months for non-responders (P = 0.02). At 6 weeks, 17 responders and 7 non-responders were identified with 
48% non-responders, respectively (P = 0.01). Mean OS was 14.1 months for responders and 7.6 months for non-responders (P = 0.02). 18 F-FDOPA MTV change at 6 weeks is a stronger predictor of overall survival (P < 0.001) than MTV change at 2 weeks (P = 0.001), whereas 18 F-FDOPA MTV change at 2 weeks (P < 0.001) is a stronger predictor for progression free survival than 18 F-FDOPA MTV change at 6 weeks (P = 0.003).
Next, absolute MTVs at baseline and follow up scans were assessed for their predictive performance. As expected, baseline MTVs do not correlate with survival (PFS and OS). Interestingly, MTVs at follow up scans do correlate with survival and ROC analysis identifies an optimal threshold tumor volume of 18 ml. This surprising result was scrutinized by performing a leave-one-out cross-validation analysis to assess how robust and sensitive this cut point was to individual values. 28 of 30 cut point result thus derived generate a value of 18 ml, with the remaining two being 16.55 ml and 18.89 ml. When applying the optimal threshold value F-FDOPA MTV at 6 weeks is also predictive of overall survival and progression free survival (P = 0.03 and P = 0.02 respectively).
Response assessment by MRI
Response by MRI was evaluated at approximately 6 weeks (5.9 ± 2.7) after starting treatment based on RANO criteria and was available for twenty-nine patients. By MRI criteria, 22 patients were classified as responders (76%), these include two complete response (CR), seven partial response (PR), and thirteen patients with stable disease (SD). The remaining 7 patients (24%) had progressive disease (PD) and were considered non-responders. MRI response was predictive of overall survival as well as progression-free survival (P = 0.01 and P < 0.001 respectively). Median overall survival for responders based on MRI criteria was 1.5 times longer Contrary to the PET study, MRI derived absolute tumor volumes did not show survival correlation. 18 
F-FDOPA-PET Changes Compared with other Predictors
Multiple clinical variables were tested by univariate and multivariate analyses (Table 3, 4).
Measurements of MTV at baseline, two weeks, and six weeks in addition to changes between these time points were modeled. Baseline characteristics such as age, number of prior recurrences, and RANO response at 6 weeks were considered in the multivariate models. Modeling all MTV measurement combinations at each time point would induce a survival bias because those who died after two weeks would not have had 6 week measurements (and thus be excluded from the model). Therefore models were run with baseline data, data up through 2 weeks, and data up through 6 weeks separately (Table 4) . By univariate analysis, OS was better if patients had fewer recurrences. Patients' age, baseline KPS, dexamethasone treatment, did not predict survival (Table 3) . 18 F-FDOPA MTVs at 2 weeks and 6 weeks, as well as their changes from baseline to 2 weeks and baseline to 6 weeks were all predictive of OS (P < 0.001, P = 0.04, P = 0.01, P = 0.01, Table 3 ). However, (Table 4) .
Similarly, longer PFS was predicted if patients had fewer prior recurrences. F-FDOPA responders survived for 12.1 mo, which is 3.5 times longer than the 3.5 mo survival for non-responders (P < 0.001). Second, this study shows that change of 18 F-FDOPA MTV at 2 weeks and at 6 weeks (P = 0.002 and P = 0.02) is also predictive of OS, albeit being not as strong a predictor as the absolute MTV at 2 weeks. Third, 18 F-FDOPA MTV as well as MTV change at two weeks after treatment initiation are predictive of PFS (P < 0.001 and P = 0.001 respectively). Fourth, responders (76%; 2 CR, 7 PR, and 13 SD), and 7 patients with PD (24%) and is predictive of OS. Median OS is 1.5 times longer for MRI responders than for MRI non-responders (11.4 vs. 7.7 mo, P = 0.03).
MRI contrast enhancement primarily reflects a disrupted blood-brain barrier (BBB), which can be influenced by changes in corticosteroid dose as well as other treatment effects such as inflammation, radiation necrosis, and postsurgical change (3). In addition, non-enhancing T2-weighted and fluid-attenuated inversion recovery sequence changes can reflect tumor recurrence as well, especially in patients on antiangiogenic therapy (31, 32) . Thus, it has been proposed by the recently published Response Assessment in Neurooncology (RANO) that changes in both enhancing and non-enhancing areas should be considered in evaluating treatment response by MRI (31, 32) .
All patients in this study had also undergone As amino acid uptake in tumors is not limited to the disruption of BBB, amino acid PET imaging is particularly advantageous in evaluating non-contrast enhancing infiltrating tumors. Amino acid imaging with 18 F-FET PET in monitoring treatment in 11 and 10 glioma patients were reported previously (15, 16) . In was shown 18 F-FET PET generally demonstrated treatment failure earlier than MRI. However, follow up 18 
F-FET-
PET was done at 6 -8 weeks after starting treatment in that study, much later than our study (15, 16) . Similar to our study, it was shown that 18 F-FET PET tumor volume change, but not the SUV change, was predictive of progression free survival. Interestingly, it was noted in our study that not only In our study, baseline 18 F-FDOPA MTV is not predictive of OS (P = 0.08) or PFS (P = 0.31) but the MTVs in the follow up studies are. This is probably due to the fact that while tumor amino acid uptake is not dependent on a permeable BBB, it is enhanced by a broken BBB (34) (35) (36) (37) . High grade gliomas have pronounced tumor neovascularization through the VEGF pathway and anti-VEGF therapy results in an apparent normalization of the highly permeable BBB (38, 39) . It is likely that baseline 18 F-FDOPA uptake is in part due to this disturbance of the BBB, thus reflecting a larger than actual tumor volume and therefore is not prognostic of survival. After "normalization" of the disturbed BBB with bevacizumab, The current study has several limitations: First, the study population was small, thus these result need to be validated in a larger prospective study. Second, the patient population is relatively heterogeneous. There was (Table 4 ).
CONCLUSION
The current study demonstrates that metabolic imaging with 18 F-FDOPA PET provides a powerful prognostic tool in assessing treatment response in recurrent high-grade glioma patients on bevacizumab therapy. This response already becomes apparent two weeks after starting treatment. As absolute MTV can be used for assessment, one Table 2 ) and a nonresponding patient (B, patient 18, Table 2 ). 
